Comparing Caladrius Biosciences (CLBS) & Ligand Pharmaceuticals (LGND)

Caladrius Biosciences (NASDAQ: CLBS) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Caladrius Biosciences and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences N/A -96.80% -43.98%
Ligand Pharmaceuticals 12.76% 7.83% 4.64%

Institutional & Insider Ownership

6.5% of Caladrius Biosciences shares are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by company insiders. Comparatively, 8.3% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Caladrius Biosciences and Ligand Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Caladrius Biosciences $35.28 million 1.01 -$32.65 million ($2.07) -1.82
Ligand Pharmaceuticals $108.97 million 29.68 -$1.63 million $0.69 222.14

Ligand Pharmaceuticals has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Caladrius Biosciences has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Caladrius Biosciences and Ligand Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 1 0 3.00
Ligand Pharmaceuticals 1 0 4 0 2.60

Caladrius Biosciences presently has a consensus target price of $7.00, suggesting a potential upside of 86.17%. Ligand Pharmaceuticals has a consensus target price of $148.00, suggesting a potential downside of 3.46%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Caladrius Biosciences is more favorable than Ligand Pharmaceuticals.

Summary

Ligand Pharmaceuticals beats Caladrius Biosciences on 9 of the 14 factors compared between the two stocks.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply